BioHarvest's Olive Cell Asset Hits Commercial Readiness, Opens CDMO Licensing
BHST sits 23% above its 52-week low of $1.371 on light trading volume (0.2× avg).
Summary
BioHarvest announced its proprietary Olive Cell composition has reached commercial readiness, completing development, scale-up, and self-affirmed GRAS status. The asset is now available for licensing through the company's CDMO business, with GMP manufacturing ready for a future partner. This is the second plant-cell-derived asset to reach this stage after VINIA, validating the Botanical Synthesis platform's repeatability. Preliminary in-vitro data showed up to 37% reduction in liver fat accumulation and 50% reduction in fibrosis markers, supporting potential liver health applications. The milestone opens a new revenue stream via licensing and manufacturing, though no customer or partner has been announced yet.
At the time of this announcement, BHST was trading at $1.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.7M. The 52-week trading range was $1.37 to $12.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.